In our previous study, we presented the later-line efficacy of dacomitinib on patients with NSCLC harboring uncommon EGFR mutations in a relatively small scale (n = 11) retrospectively, and the findings indicated a promising activity of dacomitinib (Li et al., 2022). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.